Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01358175 · ClinicalTrials.gov registry record · Phase 3
16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 371
- Enrollment target
NCT01358175 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 371 participants.
The verdict
NCT01358175, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 371 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
Interventions
- DRUG Placebo
- DRUG Secukinumab (75 mg)
- DRUG Secukinumab (150 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 371 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01358175
The ClinicalTrials.gov registry entry for NCT01358175 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 371 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01358175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01358175 about?
NCT01358175 is a clinical study titled "16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis". This study will assess the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
What is the current status of trial NCT01358175?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 371 participants. The study started on 2011-10. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01358175?
The interventions under investigation include: Placebo (DRUG), Secukinumab (75 mg) (DRUG), Secukinumab (150 mg) (DRUG).
Who is sponsoring clinical trial NCT01358175?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.